Allogene Therapeutics to Showcase Q3 Results and ALLO-329 Data in November Events

Allogene Therapeutics has scheduled two significant events in November 2026 to engage investors and share pivotal updates regarding its current research and financial performance.

Q3 Financial Results Conference Call

The company's third-quarter financial results for 2026 will be disclosed on November 5, 2026, after the market closes. This announcement will be followed by a live audio conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET).

Those interested in listening to the event can access the live webcast on Allogene's official website under the Investors tab. A replay of the conference will be available for around 30 days post-event.

Webinar on ALLO-329 Data

On November 9, 2026, at 6:00 a.m. PT (9:00 a.m. ET), Allogene will conduct a webinar to present preliminary safety and efficacy data from the Phase 1 RESOLUTION study, focusing on ALLO-329, designed for autoimmunity treatments. This study targets patients with conditions such as lupus, myositis, and scleroderma.

The upcoming webinar will precede a key poster presentation at the American College of Rheumatology's (ACR) annual meeting, ACR Convergence, slated for the same day.

About ALLO-329

ALLO-329 represents an innovative, next-gen allogeneic CAR T therapy aimed at targeting both CD19 and CD70. This therapy employs Allogene's proprietary Dagger® technology, which enhances the growth and longevity of CAR T cells and reduces the need for traditional lymphodepletion methods.

Presentations at ACR Convergence 2026

During ACR Convergence, preliminary results from the RESOLUTION trial will be shared in a poster session titled Preliminary Safety and Efficacy Results from a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T-Cell Therapy for Autoimmune Disease. This presentation will be led by Dr. Vivek Nagaraja from the Mayo Clinic Arizona and is scheduled for November 9, from 10:30 a.m. to 12:30 p.m. ET.

Allogene Therapeutics, based in South San Francisco, focuses on developing allogeneic CAR T cell therapies for both cancer and autoimmune disorders. The team behind the company consists of seasoned veterans in cell therapy, aiming to provide efficient and readily available therapies for patients worldwide. For more information on Allogene, visit their website and social media channels on X and LinkedIn.

Forward-Looking Statements

This communication contains certain forward-looking statements that fall under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements concern Allogene's objectives and expectations regarding the development and availability of its allogeneic CAR T products. Multiple factors could lead to differences between anticipated outcomes and actual results, including risks associated with innovative technologies, making predictions on product development challenging.